Suggested remit: To appraise the clinical and cost effectiveness of filgotinib within its marketing authorisation for treating moderately to severely active ulcerative colitis.
 
Status Proposed
Process STA 2018
ID number 3736

Provisional Schedule

Committee meeting: 1 05 October 2021
Expected publication 22 December 2021

Project Team

Project lead Shonagh D'Sylva

Email enquiries

Consultees

Companies sponsors Galapagos Biotech (filgotinib)
Others Department of Health and Social Care
  NHS England
  NHS Southport and Formby CCG
  NHS Stockport CCG
  Welsh Government
Patient carer groups Bladder and Bowel Community
  Colostomy UK
  Crohn’s and Colitis UK
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Ulcerative Colitis UK
Professional groups Association of Coloproctology for Great Britain and Ireland
  British Geriatrics Society
  British Society of Gastroenterology
  Primary Care Society for Gastroenterology
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Surgeons
  Royal Society of Medicine
  UK Clinical Pharmacy Association

Commentators

Associated public health groups Public Health England
  Public Health Wales
Comparator companies AbbVie (adalimumab)
  Amgen Europe (adalimumab)
  Biogen (adalimumab, infliximab)
  Celltrion Healthcare (infliximab)
  Fresenius Kabi (adalimumab)
  Janssen-Cilag (ustekinumab)
  Merck Sharp & Dohme (infliximab, golimumab)
  Pfizer (infliximab, tofacitinib)
  Sandoz (adalimumab, infliximab)
  Takeda UK (vedolizumab)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Scottish Society of Gastroenterology
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group
  Genomics England
  Guts UK
  MRC Clinical Trials Unit
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
16 February 2021 Invitation to participate
20 August 2020 - 18 September 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance